Abstract
Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Current Gene Therapy
Title:Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect
Volume: 15 Issue: 6
Author(s): Mirella Meregalli, Andrea Farini, Clementina Sitzia, Cyriaque Beley, Paola Razini, Letizia Cassinelli, Federica Colleoni, Paola Frattini, Nadia Santo, Elisabetta Galbiati, Davide Prosperi, Alessandro Tavelli, Marzia Belicchi, Luis Garcia and Yvan Torrente
Affiliation:
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Abstract: Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Export Options
About this article
Cite this article as:
Meregalli Mirella, Farini Andrea, Sitzia Clementina, Beley Cyriaque, Razini Paola, Cassinelli Letizia, Colleoni Federica, Frattini Paola, Santo Nadia, Galbiati Elisabetta, Prosperi Davide, Tavelli Alessandro, Belicchi Marzia, Garcia Luis and Torrente Yvan, Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect, Current Gene Therapy 2015; 15 (6) . https://dx.doi.org/10.2174/1566523215666150929111400
DOI https://dx.doi.org/10.2174/1566523215666150929111400 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Evaluation of Osteoporosis Risk Associated with Chronic Use of Morphine, Fentanyl and Tramadol in Adult Female Rats
Current Drug Safety Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Chemical Constituents and Cytotoxicity of Euphorbia vajravelui
Letters in Organic Chemistry Stem Cell Therapy for Spinal Cord Injury
Current Medicinal Chemistry A Review Exploring Therapeutic Worth of 1,3,4-Oxadiazole Tailored Compounds
Mini-Reviews in Medicinal Chemistry Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families
Endocrine, Metabolic & Immune Disorders - Drug Targets New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience
Current Radiopharmaceuticals VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research Minimally Invasive Transoral Surgical Treatment for Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Designing of Novel Carbonic Anhydrase Inhibitors and Activators
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Theoretical Modeling of HPV: QSAR and Novodesign with Fragment Approach
Current Computer-Aided Drug Design Design, Synthesis and In-Vitro Evaluation of Polymer-linked Prodrug of Methotrexate for the Targeted Delivery to the Colon
Letters in Drug Design & Discovery Stem Cell-Based Approaches for Intervertebral Disc Regeneration
Current Stem Cell Research & Therapy Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice
Current Genomics An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer
Mini-Reviews in Medicinal Chemistry The Mad2-Binding Protein p31<sup>comet</sup> as a Potential Target for Human Cancer Therapy
Current Cancer Drug Targets